A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2018
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Abivax
- 06 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.